Engineering Papers⌕ Search

Engineering topics

David Loftus

Publications and source records attributed to David Loftus.

4 records
All sourcesNASA NTRSDOE OSTI
NASA NTRS2024

Metabolic Suppression: A Promising Solution to Unlock the Future of Space Travel

Space tourism is no longer a distant dream but a present-day reality, with current excursions consisting of suborbital jaunts, and near future excursions to including lunar expeditions and, eventually, trips to Mars. Beneath the allure of weightlessness and cosmic views, however, lies a set of serious health risks for space travelers, including muscle and bone issues, heart problems, and cognitive impairment. In this mini review, we delve into the topic of metabolic suppression, an innovative approach to mitigating the deleterious effects of space travel that has been proposed for astronauts that may be appropriate for space tourists as well. Drawing inspiration from the survival strategies observed in hibernating animals and often depicted in sci-fi narratives where crews are in “suspended animation” throughout most of the voyage, this method involves inducing a reversible state of dormancy, akin to torpor, in human space travelers. The objective of metabolic suppression is to safeguard space travelers from the adverse impacts of extended exposure to microgravity and space radiation on long duration expeditions, so that on arrival at their destination, they can be healthy and ready to go. We shed light on ongoing research endeavors led by the National Aeronautics and Space Administration (NASA), the European Space Agency (ESA), and other prominent organizations dedicated to investing in and advancing metabolic suppression technologies for professional space travel, that may also enable space tourism to ever more distant destinations

Space Tourism↗
NASA NTRS2023

Bacillus Subtilis Engineered for Aerospace Medicine: A Platform for Off-Planet Production of Pharmaceutical Peptides

Biologics, such as pharmaceutical peptides, have notoriously short shelf lives, insufficient for long-duration space flight missions to the Moon or Mars. To enable the sustainable presence of humans on the Moon or Mars, we must develop methods for on-site production of pharmaceutical peptides in space, a concept we call the Astropharmacy. Here, we present a proof-of-concept for the first step needed: a low-mass system for pharmaceutical production designed to be stable in space. To demonstrate feasibility, we engineered strains of the space-hardy spore-forming bacterium, Bacillus subtilis, to secrete two pharmaceutical peptides important for astronaut health: teriparatide (an anabolic agent for combating osteoporosis) and filgrastim (an effective countermeasure for radiation-induced neutropenia). We found that the secretion peptides from the walM and yoqH genes of B. subtilis worked well for secreting teriparatide and filgrastim, respectively. In consideration of the Translational Research Institute for Space Health (TRISH) challenge to produce a dose equivalent in 24 h, dried spores of our engineered strains were used to produce 1 dose equivalent of teriparatide from a 2 mL culture and 1 dose equivalent of filgrastim from 52 mL of culture in 24 h. Further optimization of strain growth conditions, expression conditions, and promoter sequences should allow for higher production rates to be achieved. These strains provide the template for future optimization efforts and address the first step in the Astropharmacy, capable of on-site production, purification, and processing of biopharmaceutical compounds in platforms amenable for use in space.

Alec Vallota-Eastman↗